Pursuing Charlene's Dream

Article

Oncology nursing is more than just a job to Barbara Bittner, RN, OCN.

Barbara Bittner, RN, OCN, is an oncology nurse navigator at AdventHealth in Florida. But to her, nursing is much more than just a career. Bittner cares deeply for all of her patients, and even helped establish Charlene's Dream, a resource center for women with cancer, after her friend and Colleague, Charlene, passed away from the disease.

Related Videos
Related Content
FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC

FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC

April 18th 2024
Article

Alectinib was approved for the treatment of patients with ALK-positive non-small cell lung cancer after surgical resection.

The Vitals

What New Cancer Drugs Were Approved in 2023?

January 1st 2024
Podcast

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Lumisight and Lumicell DVS Receive FDA Approval to Detect Residual Breast Cancer

Lumisight and Lumicell DVS Receive FDA Approval to Detect Residual Breast Cancer

April 18th 2024
Article

The optical imaging agent Lumisight and the Lumicell Direct Visualization System received approval from the FDA for fluorescence imaging in breast cancer.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Tamibarotene-Based Combo Receives Fast Track Designation from the FDA for AML

Tamibarotene-Based Combo Receives Fast Track Designation from the FDA for AML

April 17th 2024
Article

The FDA granted tamibarotene plus azacitidine and venetoclax fast track designation for the treatment of newly diagnosed, unfit, RARA-overexpressed AML.

Survival Benefit Persists at 3 Years With Durvalumab Plus Chemo in Advanced Biliary Tract Cancer

Survival Benefit Persists at 3 Years With Durvalumab Plus Chemo in Advanced Biliary Tract Cancer

April 16th 2024
Article

Superior 3-year survival outcomes were observed with durvalumab plus chemotherapy compared with chemotherapy alone in patients with advanced biliary tract cancer.

© 2024 MJH Life Sciences

All rights reserved.